Myopia:the Role of Cone Opsin Mutations & Glasses That Control Axial Elongation
NCT ID: NCT01923675
Last Updated: 2019-08-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2013-11-30
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
2. To determine the effect of spectacles with a holographic diffuser that spreads incident light rays over an angle of 0.5 degrees on myopia progression in children
3. To determine the combined effects of spectacles with a red blocking filter and a diffuser that spreads incident light over an angle of 0.5 degrees on myopia progression in children.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Light Diffraction Glasses in Preventing and Controlling Myopia in Adolescents
NCT06927414
Enhancement of Emmetropization in Hyperopic Infants
NCT00574717
Different Microlenses Array for Controlling Myopia Progression in Children and Adolescents
NCT06926556
Peripheral Optics in Myopia and Orthokeratology
NCT00978679
Efficacy in Controlling Myopia in Young Children Using a Novel Spectacle Lens
NCT06034327
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The following procedures will be performed on a total of 240 children from 8 to 13 years of age:
1. Color vision tests (Richmond Hardy-Rand-Rittler pseudoisochromatic plate test and/or the Rayleigh match test and/or the Neitz Test of Color Vision), and machine-based vision tests using the Titmus tester (color vision, binocularity, acuity, and heterophoria tests);
2. each subject will provide a blood sample or a buccal swab for genetic analysis of the long and middle wavelength cone photopigment genes in order to determine the relationship between the cone opsins and myopia;
3. eye measurements including axial length and corneal curvature will be performed using the Zeiss Intraocular Lens Master;
4. cycloplegic autorefraction will be doe at the beginning of the study before participants start wearing the study spectacles, after 18 months if wearing the study spectacles, and 6 months after participants stop wearing the study spectacles.
4\) subjects will be randomly assigned to one of four groups, consisting of 60 subjects each, each group will be assigned one of four study spectacles.
The study spectacles for all participants will have the optimal lens corrections for both eyes.
Group 1 participants will wear spectacles with lenses tinted to blocks red light.
Group 2 participants will wear spectacles with lenses that have a holographic diffuser on surface of and that are tinted to reduce the light intensity by the same amount that the red-blocking tint does.
Group 3 participants will wear spectacles that are tinted to block red light and that have a holographic diffuser.
Group 4 participants will wear spectacles that are tinted to reduces the light intensity by the same amount that the red-blocking tint does.
Participants will wear the study glasses for 18 months. Axial length measurements will be taken twice prior to when subjects begin wearing the glasses and once every three month thereafter.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
color blocking tint
Spectacles with red-blocking tint subjects will wear glasses daily for 6 months and have
Spectacles with red-blocking tint
Eyeglasses will have lenses that will correct refractive error for each subject, and will have a tint that blocks red light.
holographic diffuser
Spectacles with color neutral tint subjects will wear glasses daily for 6 months and have
Spectacles with holographic diffuser and color neutral tint
Eyeglasses will correct refractive error for each subject but will have a holographic diffuser applied to the surface and will have a color neutral filter to adjust the light intensity reaching the eyes to be the same as for groups 1 and3.
diffuser & color blocking tint
Spectacles with holographic diffuser and red-blocking tint subjects will wear glasses daily for 6 months and have
Spectacles with holographic diffuser and red-blocking tint
Eyeglasses will correct refractive error for each subject and will be tinted to block red light, and will have a holographic diffuser to blur the image.
holographic diffuser and neutral tint
Spectacles with holographic diffuser and color neutral tint subjects will wear glasses daily for 6 months and have
Spectacles with color neutral tint
Eyeglasses will correct refractive error for each subject and will have a color neutral tint to adjust the light intensity reaching the eyes so it is the same as for groups 1 and 3.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Spectacles with red-blocking tint
Eyeglasses will have lenses that will correct refractive error for each subject, and will have a tint that blocks red light.
Spectacles with holographic diffuser and color neutral tint
Eyeglasses will correct refractive error for each subject but will have a holographic diffuser applied to the surface and will have a color neutral filter to adjust the light intensity reaching the eyes to be the same as for groups 1 and3.
Spectacles with holographic diffuser and red-blocking tint
Eyeglasses will correct refractive error for each subject and will be tinted to block red light, and will have a holographic diffuser to blur the image.
Spectacles with color neutral tint
Eyeglasses will correct refractive error for each subject and will have a color neutral tint to adjust the light intensity reaching the eyes so it is the same as for groups 1 and 3.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* myopia progression at least -.50 D per year in previous year
* astigmatism and anisometropia not more than 1.5 D
* distance monocular acuity 6/6 or better
* near monocular acuity of 0.4 M or better
* stereoacuity not more than 40 sec of arc at 40 cm
* able to respond to subjective testing
* no contact lens use during the study
* able to comply with wearing the experimental lenses daily for 18 months
* able to have axial length measurements accurately on the Zeiss Intraocular Lens Master
* willing to donate a blood sample or a buccal swab for genetic analysis
* can be refracted to 20/20 or 20/15
Exclusion Criteria
* ocular disease
* developmental delay
* history of wearing bifocal lenses
* any type of eye surgery
* color vision deficiency
8 Years
13 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Seattle Children's Hospital
OTHER
University of Washington
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jay Neitz
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jay Neitz, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Washington
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Washington
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Carkeet A, Saw SM, Gazzard G, Tang W, Tan DT. Repeatability of IOLMaster biometry in children. Optom Vis Sci. 2004 Nov;81(11):829-34. doi: 10.1097/01.opx.0000145020.33250.c0.
Congdon NG, Friedman DS, Lietman T. Important causes of visual impairment in the world today. JAMA. 2003 Oct 15;290(15):2057-60. doi: 10.1001/jama.290.15.2057. No abstract available.
Grosvenor T. Why is there an epidemic of myopia? Clin Exp Optom. 2003 Sep;86(5):273-5. doi: 10.1111/j.1444-0938.2003.tb03122.x. No abstract available.
Gwiazda J, Hyman L, Hussein M, Everett D, Norton TT, Kurtz D, Leske MC, Manny R, Marsh-Tootle W, Scheiman M. A randomized clinical trial of progressive addition lenses versus single vision lenses on the progression of myopia in children. Invest Ophthalmol Vis Sci. 2003 Apr;44(4):1492-500. doi: 10.1167/iovs.02-0816.
Ip JM, Rose KA, Morgan IG, Burlutsky G, Mitchell P. Myopia and the urban environment: findings in a sample of 12-year-old Australian school children. Invest Ophthalmol Vis Sci. 2008 Sep;49(9):3858-63. doi: 10.1167/iovs.07-1451. Epub 2008 May 9.
Rein DB, Zhang P, Wirth KE, Lee PP, Hoerger TJ, McCall N, Klein R, Tielsch JM, Vijan S, Saaddine J. The economic burden of major adult visual disorders in the United States. Arch Ophthalmol. 2006 Dec;124(12):1754-60. doi: 10.1001/archopht.124.12.1754.
Saw SM, Gazzard G, Shih-Yen EC, Chua WH. Myopia and associated pathological complications. Ophthalmic Physiol Opt. 2005 Sep;25(5):381-91. doi: 10.1111/j.1475-1313.2005.00298.x.
Saw SM, Katz J, Schein OD, Chew SJ, Chan TK. Epidemiology of myopia. Epidemiol Rev. 1996;18(2):175-87. doi: 10.1093/oxfordjournals.epirev.a017924. No abstract available.
Vitale S, Sperduto RD, Ferris FL 3rd. Increased prevalence of myopia in the United States between 1971-1972 and 1999-2004. Arch Ophthalmol. 2009 Dec;127(12):1632-9. doi: 10.1001/archophthalmol.2009.303.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SCH13693
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.